The Technical AnalystExchange: ASX Industry: Pharmaceuticals, Biotechnology & Life Sciences
CSL Ltd Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.15% $275.80
America/New_York / 3 mai 2024 @ 02:10
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 133 281 mill |
| EPS: | 7.85 |
| P/E: | 35.13 |
| Earnings Date: | Feb 13, 2024 |
| SharesOutstanding: | 483.25 mill |
| Avg Daily Volume: | 0.700 mill |
| RATING 2024-05-03 |
|---|
| S |
| Strong Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Buy | |
| DE: | Strong Buy | |
| P/E: | Neutral | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/21 | 4/21 | 2/22 | 4/22 | 2/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | n/a | n/a | n/a | n/a | n/a | n/a |
| Asset | n/a | n/a | n/a | n/a | n/a | n/a |
| Debt | n/a | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 27.93x |
| Company: PE 35.13 | sector: PE 1.258 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.92x |
| Company: PE 35.13 | industry: PE 38.27 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$398.21 (44.38%) $122.41 |
| Date: 2024-05-03 |
| Expected Trading Range (DAY) |
|---|
|
$ 272.07 - 279.53 ( +/- 1.35%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $275.80 (0.15% ) |
| Volume | 0.420 mill |
| Avg. Vol. | 0.700 mill |
| % of Avg. Vol | 59.98 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For CSL.AX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
CSL.AX
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and CSL Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The CSL Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza related products. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.